MedTrace Logo

Effects of Platelet Rich Plasma on Endometrium

NCT04424160 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-04-20

No results posted yet for this study

Summary

Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal route after the cessation of menstrual period. The endometrial thickness will be assessed under ultrasound and hormone replacement will be started. As the endometrial thickness reaches adequate thickness during ultrasound follow-up, embryo transfer will be performed.

Conditions

  • Asherman Syndrome

Interventions

BIOLOGICAL

PRP injection in the endometrium

Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.

Sponsors & Collaborators

  • Baskent University

    collaborator OTHER

  • Acibadem University

    lead OTHER

Principal Investigators

  • Hulusi Bulent Zeyneloglu, Prof · Baskent University Departments of Obstetrics and Gynecology

  • Yigit Cakiroglu, Assoc.Prof. · Acibadem University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2021-04-19
Completion
2021-04-19

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04424160 on ClinicalTrials.gov